Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Michael H. Le, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):284-286. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0108

View: 1872 Download: 33

Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):841-850. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0239

View: 8239 Download: 259 Web of Science: 92 Crossref: 94

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Received June 6, 2024 Accepted August 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431 [Accepted]

View: 1109 Download: 240 Crossref: 2

1 |

Viewed By 4872	MAFLD: How is it different from NAFLD?
Viewed By 4821	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4665	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4401	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4341	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search